Inter-α-trypsin inhibitor attenuates complement activation and complement-induced lung injury

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 4187-4192

  Garantziotis, Stavros ^a,b   Hollingsworth, John W ^a,b   Ghanayem, Rami B ^c   Timberlake, Sarah ^a,b   Zhuo, Lisheng ^d   Kimata, Koji ^d   Schwartz, David A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTER ALPHA TRYPSIN INHIBITOR; ALPHA GLOBULIN; COMPLEMENT; COMPLEMENT INHIBITOR; INTER ALPHA INHIBITOR; INTER-ALPHA-INHIBITOR; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; INFLAMMATION; LUNG INJURY; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; FEMALE; GENETICS; IMMUNE COMPLEX DISEASE; IMMUNOLOGY; LUNG; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING;

ALPHA-GLOBULINS; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; FEMALE; IMMUNE COMPLEX DISEASES; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN SUBUNITS;

EID: 35748965877     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.4187     Document Type: Article

References (27)

1. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12: 682-687.
2. Ward, P. A., and J. H. Hill. 1970. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J. Immunol. 104: 535-543.
3. Huber-Lang, M., E. M. Younkin, J. V. Sarma, N. Riedemann, S. R. McGuire, K. T. Lu, R. Kunkel, J. G. Younger, F. S. Zetoune, and P. A. Ward. 2002. Generation of C5a by phagocytic cells. Am. J. Pathol. 161: 1849-1859.
4. Ward, P. A. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4: 133-142.
5. Huber-Lang, M. S., E. M. Younkin, J. V. Sarma, S. R. McGuire, K. T. Lu, R. F. Guo, V. A. Padgaonkar, J. T. Curnutte, R. Erickson, and P. A. Ward. 2002. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169: 3223-3231.
6. Zhuo, L., V. C. Hascall, and K. Kimata. 2004. Inter-α-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. J. Biol. Chem. 279: 38079 -38082.
7. Lim, Y. P., K. Bendelja, S. M. Opal, E. Siryaporn, D. C. Hixson, and J. E. Palardy. 2003. Correlation between mortality and the levels of inter-α inhibitors in the plasma of patients with severe sepsis. J. Infect. Dis. 188: 919-926.
8. Jourdain, M., O. Carrette, A. Tournoys, F. Fourrier, C. Mizon, J. Mangalaboyi, J. Goudemand, J. Mizon, and C. Chopin. 1997. Effects of inter-α-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am. J. Respir. Crit. Care Med. 156: 1825-1833.
9. Yang, S., Y. P. Lim, M. Zhou, P. Salvemini, H. Schwinn, D. Josic, D. J. Koo, I. H. Chaudry, and P. Wang. 2002. Administration of human inter-α-inhibitors maintains hemodynamic stability and improves survival during sepsis. Crit. Care Med. 30: 617-622.
10. Opal, S. M., A. W. Artenstein, P. A. Cristofaro, J. W. Jhung, J. E. Palardy, N. A. Parejo, and Y. P. Lim. 2005. Inter-α-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. Infect. Immun. 73: 5101-5105.
11. Misumi, Y., K. Oda, T. Fujiwara, N. Takami, K. Tashiro, and Y. Ikehara. 1991. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J. Biol. Chem. 266: 16954-16959.
12. Zhuo, L., M. Yoneda, M. Zhao, W. Yingsung, N. Yoshida, Y. Kitagawa, K. Kawamura, T. Suzuki, and K. Kimata. 2001. Defect in SHAP-hyaluronan complex causes severe female infertility: a study by inactivation of the bikunin gene in mice. J. Biol. Chem. 276: 7693-7696.
13. Sung, S. S., R. S. Nelson, and S. C. Silverstein. 1983. Yeast mannans inhibit binding and phagocytosis of zymosan by mouse peritoneal macrophages. J. Cell Biol. 96: 160-166.
14. Vachon, E., R. Martin, J. Plumb, V. Kwok, R. W. Vandivier, M. Glogauer, A. Kapus, X. Wang, C. W. Chow, S. Grinstein, and G. P. Downey. 2006. CD44 is a phagocytic receptor. Blood 107: 4149-4158.
15. Guo, R. F., and P. A. Ward. 2002. Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radical Biol. Med. 33: 303-310.
16. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
17. Kirschfink, M. 2001. Targeting complement in therapy. Immunol. Rev. 180: 177-189.
18. Wu, R., X. Cui, Y. P. Lim, K. Bendelja, M. Zhou, H. H. Simms, and P. Wang. 2004. Delayed administration of human inter-α inhibitor proteins reduces mortality in sepsis. Crit. Care Med. 32: 1747-1752.
19. Solomon, S., D. Kassahn, and H. Illges. 2005. The role of the complement and the FcγR system in the pathogenesis of arthritis. Arthritis Res. Ther. 7: 129-135.
20. Kida, D., M. Yoneda, S. Miyaura, T. Ishimaru, Y. Yoshida, T. Ito, N. Ishiguro, H. Iwata, and K. Kimata. 1999. The SHAP-HA complex in sera from patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 26: 1230-1238.
21. Yingsung, W., L. Zhuo, M. Morgelin, M. Yoneda, D. Kida, H. Watanabe, N. Ishiguro, H. Iwata, and K. Kimata. 2003. Molecular heterogeneity of the SHAP-hyaluronan complex: isolation and characterization of the complex in synovial fluid from patients with rheumatoid arthritis. J. Biol. Chem. 278: 32710-32718.
22. Boackle, S. A. 2003. Complement and autoimmunity. Biomed. Pharmacother. 57: 269-273.
23. Hinshelwood, J., D. I. Spencer, Y. J. Edwards, and S. J. Perkins. 1999. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionization affinity mass spectrometry and homology modelling: implications for the activity of factor B. J. Mol. Biol. 294: 587-599.
24. Hui, K. M., G. L. Orriss, T. Schirmer, B. Magnadottir, J. A. Schifferli, and J. M. Inal. 2005. Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT. Biochem. J. 389: 863-868.
25. Sahu, A., and J. D. Lambris. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180: 35-48.
26. Fries, E., and A. M. Blom. 2000. Bikunin: not just a plasma proteinase inhibitor. Int. J. Biochem. Cell Biol. 32: 125-137.
27. Wakahara, K., H. Kobayashi, T. Yagyu, H. Matsuzaki, T. Kondo, N. Kurita, H. Sekino, K. Inagaki, M. Suzuki, N. Kanayama, and T. Terao. 2005. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor-α and interleukin-1β in macrophages. J. Infect. Dis. 191: 930-938.